2025 Nobel Prize: A Milestone for Autoimmunity Research – Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
Jan Hartmann, Chief Medical Officer at Haemonetics, shared on LinkedIn:
‘‘2025 Nobel Prize: A Milestone for Autoimmunity Research
This year’s Nobel Prize in Physiology or Medicine was awarded to Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their groundbreaking discoveries in peripheral immune tolerance, specifically the identification and function of regulatory T cells (Tregs) and the pivotal role of the FOXP3 gene.
Their work has transformed our understanding of how the immune system distinguishes between self and non-self—and how it prevents destructive autoimmune responses.
These insights offer a deeper understanding of autoimmune diseases, including Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Myasthenia Gravis (MG).
In both conditions, the immune system mistakenly attacks components of the nervous system, leading to debilitating symptoms.
Research suggests that patients with CIDP and MG may exhibit deficient or dysfunctional Tregs, and reduced FOXP3 expression, contributing to the breakdown of immune tolerance.
Immunoglobulin Therapies: A Cornerstone of Care
While the Nobel laureates’ discoveries are foundational, they also reinforce the importance of existing therapies.
For example, intravenous and subcutaneous immunoglobulin (IVIG/SCIG) have long been a mainstay in the treatment of CIDP and MG.
These plasma-derived medicines help modulate immune responses and mitigate the consequences of unregulated autoimmunity.
The convergence of Nobel-level science and clinical practice underscores a powerful message: a deeper understanding of immune regulation is key to advancing therapies—both established and emerging.”
Read more on Nobel Prize in Physiology or Medicine 2025.
Stay updated on the important with Hemostasis Today.
-
Jan 12, 2026, 14:46A Behcet Disease with Aortic Thrombosis: Alexandru Stieber Shares A Peculiar Case
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies